Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189224 | 0.85 | GRIN2B (0.48) | S1PR5S1PR1FUCA1DRD4GRIN2B | |
| SCHEMBL5105573 | 0.83 | CHRM3 (0.46) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL5105568 | 0.83 | CHRM3 (0.46) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL8222010 | 0.82 | NPFFR1 (0.49) | S1PR5S1PR1DRD2KMT2ASIGMAR1 | |
| SCHEMBL4618464 | 0.81 | S1PR1 (0.41) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL4686638 | 0.80 | LMNA (0.60) | KMT2A | |
| SCHEMBL4687584 | 0.80 | LMNA (0.60) | KMT2A | |
| SCHEMBL4241235 | 0.80 | FAAH (0.49) | S1PR5S1PR1FAAHDRD3 | |
| SCHEMBL4619124 | 0.80 | S1PR5 (0.41) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL5099505 | 0.80 | CHRM3 (0.45) | S1PR5S1PR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | S1PR5 4496/4885S1PR1 4167/4885FUCA1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.